Amarin Corp Plc (AMRN)

[sts66]

ANCHOR studies, this newly published analysis of these studies shows that Vascepa 4g/day significantly decreased levels of several inflammatory markers relative to placebo, including oxidized low-density lipoprotein (Ox-LDL), lipoprotein-associated phospholipase A2 (Lp-PLA2), and high sensitivity C-reactive protein (hsCRP).

Only problem is that the medical community has not accepted those markers as valid indicators of CV risk - insurance won't pay for any of them because they're still "experimental", despite mountains of evidence that they are the best markers we have. Likely one of the reasons AMRN was not allowed to speak about V's effect on them at the AC, even though Crestor was apparently approved just on it's ability to lower CRP!?! Different treatment for the big guy vs. the little guy, who didn't grease the right palms.